Paul LePage: SYRINGE EXCHANGES

In 2016, Bipartisan Majorities Overrode LePage’s Veto of a Bill That Established a Methodology for Distributing Syringe Exchange Funds to Programs Certified by DHHS. In April 2016, the House overrode LePage’s veto of LD1552 by a 108-40 vote and the Senate by a 25-9 vote. LD1552 “establishes a methodology for distributing funds for the hypodermic apparatus exchange programs certified by the Department of Health and Human Services, Maine Center for Disease Control and Prevention and allows the center to amend the rules with respect to the distribution of funds, renewal of certification, complaint investigation procedures and decertification criteria. The center must allocate funds appropriated for existing hypodermic apparatus exchange programs among programs based on rates of intravenous drug use and negative health outcomes related to drug use in the geographic area surrounding a program and the amount of services historically provided by the program although funds awarded in order to facilitate the operation of programs in counties without a program may be awarded through a competitive grant process.” [Summaries of Bills, LD1552, 2016; Maine State Legislature, LD1552, 2016]

  • The Bill Promulgated Regulatory Rules But Did Not Appropriate Funds to Support the New Rules. According to the Maine Department of Health and Human Services, “The ban on using federal funds to support exchange activities was lifted on January 6, 2016. The Maine Legislature passed LD 1552 (An Act To Reduce Morbidity and Mortality Related to Injection Drugs) in the spring of 2016, but no funds were appropriated to support this action. Additional regulatory rules were also promulgated through this statute (10-144 CMR c.252). The Maine Legislature passed LD 1707 (An Act To Reduce the Cost of Care Resulting from Blood-borne Infectious Diseases) July 9, 2018. This bill provides funds to support hypodermic apparatus, or syringe, exchange programs. This funding is due to be distributed to the three state-certified Hypodermic Apparatus Exchange Program Operators in early 2019.” [Maine Department of Health and Human Services, 2018]
  • The Needle Exchange Program Was Initially Funded With General Fund Funding, But The Funding Language Was Stripped From The Bill As Enacted. “-- LD 1552, An Act to Reduce Morbidity and Mortality Related to Injected Drugs. The $75,000 cost of a needle-exchange program originally was funded with general fund dollars, but the funding language was stripped before the bill's enactment. The Legislature intended for the bill to be funded out of Maine Center for Disease Control funds.” [Bangor Daily News, 6/27/16]
  • LePage Said He Vetoed the Legislation Because it Didn’t Provide a Funding Source for the Needle Exchange Programs. According to LePage’s veto letter for LD1552, “This bill establishes a hypodermic needle exchange program whereby the Maine Center for Disease Control and Prevention is required to provide funding to needle exchange operators. However, the Legislature did not appropriate any money to fund this program.” [Gov. LePage Veto Letter for LD1552, 4/26/16]
  • 6/27/16: Governor LePage Issued An Executive Order Funding The Needle Exchange Program, Which Democratic Legislative Leaders Called A Campaign Stunt. “Gov. Paul LePage has issued an executive order related to four bills he says the Legislature refuses to properly fund. Democratic House Speaker Mark Eves of North Berwick said the situation was a campaign stunt. LePage says he'll use money from the Low-Cost Drugs for Maine's Elderly Program, the Fund for a Healthy Maine and personal services accounts to fund the bills and may resort to a hiring freeze with the Department of Health and Human Services to find the funding. […] The four bills are: […] -- LD 1552, An Act to Reduce Morbidity and Mortality Related to Injected Drugs. The $75,000 cost of a needle-exchange program originally was funded with general fund dollars, but the funding language was stripped before the bill's enactment. The Legislature intended for the bill to be funded out of Maine Center for Disease Control funds.” [Bangor Daily News, 6/27/16]

In 2018, Bipartisan Majorities of the House and Senate Overrode LePage’s Veto Of A Bill That Funded A Clean Syringe Exchange. In July 2018, the House overrode LePage’s veto of LD1707 by a 102-40 vote and the Senate by a 25-8 vote. “Among the bills caught in LePage’s crosshairs were LD1707, which would fund clean hypodermic syringe exchange; LD1711, a pilot project of low-barrier treatment and housing for homeless opioid users; LD105, which sought to establish a Substance Use Disorder Cabinet in the Maine Legislature; and LD812, which would establish a pilot project in Washington County for residents seeking treatment and recovery support for substance use disorders.” The House overrode LePage’s veto by a 102-40 vote and the Senate by a 25-8 vote, and the bill became law. [Maine Beacon, 7/9/18; Maine State Legislature, LD 1707, Roll Call #711, 7/9/18]

  • The Needle Exchange Program Would “Create New Access Points For Entry To Treatment And Recovery Programs.” “Also approved over LePage’s veto was a $75,000 needle-exchange program, part of a harm-reduction strategy that is meant not only to help stop the spread of infectious diseases such as hepatitis C and HIV, but also to create new access points for entry to treatment and recovery programs.” [Portland Press Herald, 7/16/18]
  • HEADLINE: “Despite Rising Death Toll, LePage Vetoes Opioid Treatment Bills.” [Maine Beacon, 7/9/18]
  • LePage On Needle Exchange Program Veto: Program Provided “Path for A Person To Participate In Dangerous, Destructive And Deadly Behavior.” “In his veto letter on the needle-exchange bill, LePage wrote, ‘I do not believe it is the government's responsibility to ensure that we provide the safest possible path for a person to participate in dangerous, destructive and deadly behavior.’ He said he was working with the Maine Department of Health and Human Services to ‘make it a priority to invest in evidence-based treatment options that will produce the best outcomes for individuals dealing with addiction.’" [Press Herald, 7/16/18]

Source report (PDF)